Tatva Chintan Pharma Chem Ltd

Tatva Chintan Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Tatva Chintan Pharma Chem Ltd

₹ 1,158 -2.09%
26 May - close price
tatvachintan.com BSE: 543321 NSE: TATVA
About

Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]

Key Points

Product Portfolio:
Tatva Chintan has a portfolio of 214 products divided into 4 categories: [1]
a) Pharmaceuticals & Agrochemicals Intermediates and other Specialty Chemicals (PASC):[2][3] PASC is used to produce intermediates, catalysts, and solvents for industries like pharmaceuticals, agrochemicals, and disinfectants. The company specializes in manufacturing Glymes, a solvent essential for API production. It is India's largest Glyme producer and ranks 3rd globally. [4] [5] [6]
b) Structure Directing Agents (SDA):
The company manufactures SDAs, a crucial raw material for producing high-precision zeolites, which find industrial uses as catalysts and adsorbents across automotive, petrochemicals and other industries. It is the 2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India.[7] [6]
c) Phase Transfer Catalyst (PTC):
The company is India’s leading producer of PTC. PTCs play a key role in heterogeneous multiphase systems by aiding reactant migration. They are utilized in pharmaceutical APIs, agrochemicals, flavors and fragrances, and environmental control processes.[7][6]
d) Electrolyte Salts & Others:
Electrolyte Salts are used to manufacture supercapacitor batteries. The company is India’s largest producer of electrolyte salts and solutions for supercapacitor batteries. It also manufactures Brominated Flame Retardants, essential in the construction, electronics, and automotive industries. [8]

Website BSE NSE
  • Market Cap ₹ 2,710 Cr.
  • Current Price ₹ 1,158
  • High / Low ₹ 1,610 / 863
  • Stock P/E 64.4
  • Book Value ₹ 334
  • Dividend Yield 0.09 %
  • ROCE 7.14 %
  • ROE 5.53 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company's working capital requirements have reduced from 133 days to 92.0 days

Cons

  • Stock is trading at 3.47 times its book value
  • The company has delivered a poor sales growth of 11.0% over past five years.
  • Company has a low return on equity of 3.68% over last 3 years.
  • Promoter holding has decreased over last 3 years: -7.15%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE Commodities BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
125 114 97 84 98 105 83 86 108 117 124 131 134
108 93 76 73 83 93 78 79 99 100 101 106 106
Operating Profit 16 21 20 11 16 13 6 7 9 17 22 25 28
OPM % 13% 19% 21% 13% 16% 12% 7% 8% 8% 15% 18% 19% 21%
-3 1 1 1 5 1 0 0 1 1 1 2 -0
Interest 3 3 3 0 0 0 0 0 0 0 1 0 1
Depreciation 3 6 7 7 6 7 7 7 7 9 9 9 10
Profit before tax 8 13 11 5 14 7 -1 -0 2 9 14 18 17
Tax % -117% 29% 31% 34% 30% 24% -34% -165% 49% 27% 27% 14% 38%
17 10 8 3 10 5 -1 0 1 7 10 15 10
EPS in Rs 7.65 4.29 3.33 1.48 4.11 2.23 -0.28 0.06 0.44 2.84 4.24 6.49 4.41
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
136 206 263 300 434 424 394 383 506
113 172 208 234 325 363 325 348 413
Operating Profit 23 34 55 67 109 61 69 35 93
OPM % 17% 17% 21% 22% 25% 14% 17% 9% 18%
1 1 1 5 9 2 7 2 4
Interest 3 4 4 4 5 9 7 2 3
Depreciation 3 4 5 7 8 10 26 28 37
Profit before tax 19 27 48 61 104 45 44 8 57
Tax % 35% 25% 21% 14% 8% -2% 30% 25% 26%
12 21 38 52 96 45 30 6 42
EPS in Rs 15.30 25.56 47.03 26.02 43.25 20.52 12.97 2.44 17.98
Dividend Payout % 0% 0% 0% 19% 5% 10% 15% 41% 0%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: 6%
TTM: 32%
Compounded Profit Growth
10 Years: %
5 Years: -4%
3 Years: -5%
TTM: 633%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -11%
1 Year: 28%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: 4%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 8 8 8 20 22 22 23 23 23
Reserves 51 72 110 146 451 493 714 715 758
56 77 91 90 120 170 14 36 120
28 31 41 59 65 74 67 61 102
Total Liabilities 144 188 249 315 658 759 819 836 1,004
57 67 111 120 160 196 427 526 611
CWIP 10 6 5 10 51 231 77 27 23
Investments 1 0 0 0 0 0 10 0 4
76 115 133 185 447 332 305 283 365
Total Assets 144 188 249 315 658 759 819 836 1,004

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
13 7 25 20 20 28 98 25 31
-30 -17 -40 -21 -197 -101 -121 -65 -116
7 17 10 -5 235 38 31 17 79
Net Cash Flow -10 8 -5 -6 59 -36 8 -24 -5
Free Cash Flow -18 -2 -23 -1 -69 -175 -30 -51 -82
CFO/OP 105% 39% 61% 44% 36% 61% 157% 84% 42%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 77 73 69 110 48 73 65 79 86
Inventory Days 148 114 175 173 319 262 320 246 319
Days Payable 127 71 87 114 83 52 94 60 95
Cash Conversion Cycle 99 116 157 169 283 283 291 264 310
Working Capital Days 15 46 47 74 74 25 158 148 92
ROCE % 22% 28% 28% 26% 9% 7% 1% 7%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Combined Assembly Lines
Nos

Log in to view insights

Please log in to see hidden values.

Login
Combined Installed Reactor Capacity
KL
Quality Control and QA Employees
Nos
R&D Employees
Nos
Pharma & Agro Intermediates (PASC) Revenue
INR Mn
Phase Transfer Catalyst (PTC) Revenue
INR Mn
Structured Directing Agents (SDA) Revenue
INR Mn
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
79.17% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02%
3.19% 4.40% 4.21% 3.65% 3.37% 3.33% 3.36% 3.30% 3.26% 3.40% 4.17% 3.81%
11.07% 13.78% 13.06% 12.84% 10.64% 6.83% 6.34% 5.46% 5.11% 3.87% 3.32% 2.99%
6.56% 9.79% 10.72% 11.49% 13.97% 17.81% 18.27% 19.21% 19.60% 20.72% 20.49% 21.16%
No. of Shareholders 70,79974,62874,51973,73073,91279,62379,00978,39376,79273,33168,65766,842

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls